Why did 9939.HK stock fall so sharply today?

The intraday fall followed a gap open at HK$4.60 and large volume of 24,511,500.00 shares. Traders cited earnings season and clinical-readout uncertainty ahead of the 26 Mar 2026 announcement. High relative volume increased selling pressure.

What are the short-term technical levels for 9939.HK stock?

Key intraday support is HK$3.01 with resistance at the middle Bollinger band HK$3.22. RSI at 47.86 is neutral; ADX 43.90 signals a strong trend. Watch VWAP and volume for follow-through.

How does Meyka AI view 9939.HK stock valuation and forecast?

Meyka AI rates 9939.HK **62.80** (Grade B, HOLD). The model projects HK$2.79 monthly and HK$3.03 quarterly targets. These figures imply downside and are model-based projections, not guarantees.

What are the main risks for investors in 9939.HK stock?

Primary risks are clinical trial outcomes, regulatory review, tight liquidity (current ratio 0.44), negative operating cash flow, and high valuation relative to sector peers. Positive trial news would materially alter the outlook.

HK Stocks

9939.HK stock down 25.54% intraday 20 Mar 2026 HKSE: assess liquidity impact

ByDanny Kontos March 20, 2026

9939.HK stock fell 25.54% to HK$3.12 intraday on 20 Mar 2026 on the HKSE, driven by a sharp sell-off from the opening price of HK$4.60 and a volume spike of 24,511,500.00 shares. The drop widens volatility ahead of an earnings announcement scheduled for 26 Mar 2026 and places focus on liquidity and clinical-readout risk for Kintor Pharmaceutical Limited. We track trading signals, valuation gaps, and short-term price targets to help investors parse the move.